When the body is in a caloric deficit, whether produced by dieting, appetite suppression, or GLP-1 medication, it draws energy from multiple sources. Some comes from stored fat. Some comes from skeletal muscle. The ratio between the two determines the quality of the weight loss outcome, not just its quantity. Losing twenty kilograms that is fifty percent fat and fifty percent muscle produces a very different physiological outcome than losing the same twenty kilograms that is ninety percent fat.
What the Clinical Trials Actually Found
The STEP 1 trial of semaglutide, published in the New England Journal of Medicine in 2021, found that of the total weight lost, approximately 38 percent was lean mass. A subsequent analysis of the STEP programme using dual-energy X-ray absorptiometry confirmed substantial reductions in lean mass alongside fat mass. In absolute terms, participants losing approximately fifteen kilograms of total weight lost around five to six kilograms of lean tissue. A 2024 review in the journal Obesity Reviews, examining multiple GLP-1 trials, confirmed this pattern across semaglutide and tirzepatide studies.
The SURMOUNT-1 trial of tirzepatide found similar proportional lean mass loss despite greater total weight reduction. Because tirzepatide produces larger absolute weight losses, the absolute amount of lean mass lost can be greater even if the proportion is similar. A participant losing twenty-two kilograms on tirzepatide may lose seven to eight kilograms of lean mass without an active resistance training programme.
Why This Matters More After 40
Adults lose skeletal muscle naturally from their mid-thirties at a rate of approximately 1 percent per year, accelerating after 60. This process, sarcopenia, is one of the most significant biological drivers of functional decline, metabolic disease, and reduced longevity. Losing an additional five to eight kilograms of lean mass in the space of twelve to eighteen months of GLP-1 treatment superimposes a decade or more of sarcopenic decline onto the baseline rate of age-related muscle loss. The body does not distinguish between muscle lost through ageing and muscle lost through medically induced caloric restriction.
The metabolic consequences are compounded. Skeletal muscle is the primary site of glucose disposal. Less muscle means lower insulin sensitivity, reduced resting metabolic rate, and a higher proportion of body fat even at the same total body weight. An adult who loses fifteen kilograms on semaglutide but loses five kilograms of that as muscle may end the treatment at a lower scale weight but with a worse body composition ratio than they had when they began.
What Reduces the Muscle Loss
Two interventions consistently reduce lean mass loss during GLP-1 treatment in clinical and observational data: progressive resistance training and adequate protein intake. The STEP-HFpEF trial of semaglutide in heart failure found that participants who combined medication with structured exercise preserved more lean mass than those who received medication alone. Protein targets of 1.6 to 2.2 grams per kilogram of body weight daily, with resistance training at least three times per week, appear to meaningfully attenuate lean mass loss even during significant caloric restriction.
- Approximately 25 to 40 percent of weight lost on GLP-1 drugs is lean mass without specific intervention
- Semaglutide: participants losing 15kg may lose 5 to 6kg as lean mass
- Tirzepatide: participants losing 22kg may lose 7 to 8kg as lean mass
- Lean mass loss accelerates sarcopenia risk, particularly in adults over 50
- Resistance training three or more times per week significantly reduces the proportion of lean mass lost
- Protein intake of 1.6 to 2.2g per kilogram of body weight daily is essential throughout treatment